The monoclonal antibody MPDL3280A, a PD-L1 inhibitor being developed by Genentech, generated pharmacodynamic responses as measured by circulating biomarkers in phase 1a studies in patients with triple negative breast cancer.
In patients with metastatic triple-negative breast cancer, immunotherapy with the monoclonal antibody MPDL3280A appeared to be safe, tolerable, and capable of durable clinical activity, according to results from an ongoing multicenter phase Ia study. "The latest analysis of our data revealed a 24-week progression-free survival rate of 27% with an objective response rate of 19%, and 3 of 4 responses are ongoing," reported Leisha A. Emens, MD, PhD, of Johns Hopkins University, and colleagues in a press release at the American Association for Cancer Research annual meeting.
"MPDL3280A was generally well tolerated and demonstrated promising efficacy in pretreated metastatic PD-L1 IHC 2 or 3 TNBC patients," she added. "Furthermore, circulating biomarker analyses revealed pharmacodynamic responses to MPDL3280A."
Link to the complete article on Medpage: http://bit.ly/1Gafe7B
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More